Comprehensive molecular and clinicopathological analysis of vascular malformations: A study of 319 cases by Broek, R.W. ten et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/204299
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
R E S E A R CH AR T I C L E
Comprehensive molecular and clinicopathological analysis of
vascular malformations: A study of 319 cases
Roel W. Ten Broek1† | Astrid Eijkelenboom1† | Carine J. M. van der Vleuten2,3 |
Eveline J. Kamping4 | Marleen Kets4,3 | Bas H. Verhoeven5,3 | Katrien Grünberg1 |
Leo J. Schultze Kool6,3 | Bastiaan B. J. Tops7 | Marjolijn J. L. Ligtenberg1,4† | Uta Flucke1,7,3†
1Department of Pathology, Radboud
University Medical Center, Nijmegen, The
Netherlands
2Department of Dermatology, Radboud
University Medical Center, Nijmegen, The
Netherlands
3Radboudumc Expertise Center for
Hemangiomas and Congenital Vascular
Anomalies Nijmegen (Hecovan), Radboud
University Medical Center, Nijmegen, The
Netherlands
4Department of Human Genetics, Radboud
University Medical Center, Nijmegen, The
Netherlands
5Department of Surgery, Radboud University
Medical Center, Nijmegen, The Netherlands
6Department of Radiology and Nuclear
Medicine, Radboud University Medical Center,
Nijmegen, The Netherlands
7Princess Máxima Center for Pediatric
Oncology, Utrecht, The Netherlands
Correspondence
Uta Flucke, Radboud University Medical
Center, Department of Pathology, P.O. Box
9101, 6500 HB Nijmegen, The Netherlands.
Email: uta.flucke@radboudumc.nl
Abstract
Vascular malformations are part of overgrowth syndromes characterized by somatic mosaic
mutations or rarely by germline mutations. Due to their similarities and diversity, clinicopatho-
logical classification can be challenging. A comprehensive targeted Next Generation Sequencing
screen using Unique Molecular Identifiers with a technical sensitivity of 1% mutant alleles was
performed for frequently mutated positions in ≥21 genes on 319 formalin-fixed paraffin-embed-
ded samples. In 132 out of 319 cases pathogenic mosaic mutations were detected affecting
genes previously linked to vascular malformations e.g. PIK3CA (n=80), TEK (TIE2) (n=11), AKT1
(n=1), GNAQ (n=7), GNA11 (n=4), IDH1 (n=3), KRAS (n=9), and NRAS (n=1). Six cases harbored a
combination of mutations in PIK3CA and in GNA11 (n=2), GNAQ (n=2), or IDH1 (n=2). Aberra-
tions in PTEN and RASA1 with a variant allele frequency approaching 50% suggestive of germ-
line origin were identified in six out of 102 cases tested; four contained a potential second hit at
a lower allele frequency. Ninety-one of the total 142 pathogenic mutations were present at a
variant allele frequency <10% illustrating the importance of sensitive molecular analysis. Clinico-
pathological characteristics showed a broad spectrum and overlap when correlated with molec-
ular data. Sensitive screening of recurrently mutated genes in vascular malformations may help
to confirm the diagnosis and reveals potential therapeutic options with a significant contribution
of PIK3CA/mTOR and RAS-MAPK pathway mutations. The co-existence of two activating path-
ogenic mutations in parallel pathways illustrates potential treatment challenges and underlines
the importance of multigene testing. Detected germline mutations have major clinical impact.
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1 | INTRODUCTION
Somatic overgrowth syndromes encompass entities with predominant
vascular malformations on the one hand and conditions with more
pronounced overgrowth of tissue with only a limited vascular compo-
nent on the other hand.1–4 This spectrum of lesions is characterized
by pathogenic somatic mosaic mutations resulting in a variable
clinicopathological presentation.5 Most of these mutations are activat-
ing in genes related to cell growth, proliferation, survival, and cell cycle
progression.6 In comparison with rare familial vascular malformation
syndromes that occur with typical patterns of inheritance,7 sporadic
cases are more common.8
Recurrently mutated genes were identified in several vascular
anomalies including overgrowth/vascular malformation syndromes
like PIK3CA-related overgrowth syndrome (PROS),2,8–11 Proteus syn-
drome (activating mutations in AKT1),12 Sturge Weber syndrome† Authors contributed equally.
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(activating mutations in GNAQ)13 and Maffucci syndrome (transform-
ing mutations in IDH1 and IDH2).14
Other somatically mutated genes comprise TEK/TIE2 (activating
mutations, mainly described in venous malformations),8 KRAS, NRAS,
and HRAS (activating mutations, mainly described in arteriovenous
malformations),15,16 GLMN (disrupting mutations in glomuvenous mal-
formations)17 and GNA11 and GNA14 (activating mutations in vascular
lesions described as vascular tumors including congenital tufted angio-
mas and kaposiform hemangioendotheliomas).18
Germline RASA1-mutations have been described in patients with
Parkes Weber Syndrome and Capillary Malformation-ArterioVenous
Malformations (CM-AVM).19,20 The PTEN Hamartoma Tumor Syn-
drome includes Bannayan-Riley-Ruvalcaba syndrome (BRRS) and
Cowden syndrome (CS) harboring disrupting (germline) mutations in
PTEN. 21,22 Hereditary hemorrhagic telangiectasia bears disrupting
germline mutations in ENG and ACVRL1.19 Other known syndromes
and disorders that may include vascular anomalies are Beckwith-
Wiedemann syndrome, Noonan syndrome, Turner's syndrome, Kline-
felters syndrome, and Neurofibromatosis.1
To gain better insight into the biology of vascular malformations
and overgrowth syndromes, their mutational spectrum and potential
therapeutic options, we performed Next Generation Sequencing
(NGS) analysis with a sensitivity of 1% variant allele frequency to
allow detection of low abundant mosaic mutations in formalin-fixed
paraffin-embedded (FFPE) tissue from 319 clinical cases.
2 | MATERIALS AND METHODS
The 319 included cases are combined from a prospective and a retro-
spective cohort. The prospective samples (n = 217) were from routine
diagnostics. The retrospective samples, (n = 102) retrieved from our
pathology files, were all histologically reviewed and if possible, clinically
and radiologically confirmed as vascular malformation according to the
INTERNATIONAL SOCIETY FOR THE STUDY OF VASCULAR ANOM-
ALIES (ISSVA) classification. In a few cases a somatic overgrowth syn-
drome (SOGS) without a prominent vascular component was
diagnosed. The study was conducted in accordance with the Code of
Conduct of the Federation of Medical Scientific Societies in the Nether-
lands after consent of the internal ethical review board (2016-2310).
All samples were fixed in 4% buffered formalin, routinely pro-
cessed and embedded in paraffin. Four micrometer thick sections
were stained with hematoxylin and eosin.
DNA isolation and library preparation were performed as previ-
ously described.23,24 Briefly, gDNA was isolated from FFPE tissue
sections (generally 3 × 20 μm) using 5% Chelex-100 and 400 μg
proteinase K and DNA concentrations were measured using the
Qubit Broad Range kit (Q32853; ThermoFisher). When available,
150 ng of gDNA representing an equivalent of ~25 000 cells was
used per library preparation. In the remaining cases, the available
amount of DNA was used with a minimum of 5 ng representing
gDNA from approximately 800 cells.
Libraries for sequencing on the NextSeq 500 (Illumina) were
generated using Single Molecule Molecular Inversion Probes
(smMIPs).24 This method uses unique molecule identifiers (UMI's) to
allow consensus-based error correction and the deduction of the
actual number of sequenced gDNA molecules. Variant calling
required detection of ≥3 mutant gDNA molecules representing a
minimum of 1% of the total unique coverage. The strand-specific
nature allows the distinction between deamination artifacts from
genuine C:G > T:A mutations.24 This method therefore allows both
sensitive detection of variants down to 1% variant allele frequency
and specification of the sensitivity of sequencing on a case-by-case
basis.
The prospective cohort was analyzed using a panel targeting the
following “cancer” hotspots and surrounding sequences (the exact
positions analyzed for variants are shown in Eijkelenboom et al24):
AKT1 (NM_005163.2): codon 17; BRAF (NM_004333.4): codon
582-615; CTNNB1 (NM_001904.3): codon 19-48; EGFR
(NM_005228.3): codon 465-499, 688-823, 849-875; ERBB2
(NM_004448.3): codon 770-785; GNA11 (NM_002067.4): codon
183 and 209; GNAQ (NM_002072.3): codon 183 and 209; GNAS
(NM_000516.4): codon 201 and 227; H3F3A (NM_002107.4): codon
28 and 35; H3F3B (NM_005324.4): codon 37; HRAS (NM_005343.2):
codon 12, 13, 59 and 61; IDH1 (NM_005896.3): codon 132; IDH2
(NM_002168.3): codon 140 and 172; JAK2 (NM_004972.3):
codon 617; KIT (NM_000222.2): codon 412-513, 550-591,
628-713, 799-828; KRAS (NM_004985.4): codon 12, 13, 59, 61,
117 and 146; MPL (NM_005373.2): codon 515; MYD88
(NM_002468.4): codon 265; NRAS (NM_002524.4): codon 12, 13,
59, 61, 117 and 146; PIK3CA (NM_006218.2): codon 520-554,
1020-1069; PDGFRA (NM_006206.4): codon 552-596, 632-667,
814-848.24
For the retrospective cohort our panel was supplemented with
GNA14 (NM_004297.3) codon 205, 206; PIK3CA (NM_006218.2):
codon 420 and TEK (NM_000459.4) codon 897, 915-920, 925, 1100;
exons 3 and 13 of GLMN (NM_053274); PTEN (NM_000314), RASA1
(NM_002890), ACVRL1 (NM_000020) and ENG (NM_001114753)
(smMIP sequences of these genes are shown in Supporting Information
Table S1.
We excluded cases without identified (likely) pathogenic muta-
tions if less than 125 individual genomic DNA (gDNA) molecules were
analyzed at the frequently mutated positions. For NGS analyses above
this threshold, the presence of mutations with an allele frequency
> 5% could be excluded with 95% confidence.24 A total of 286 cases
(89.6%) fulfilled these requirements for reliable analysis.
No informed consent for the possibility of detecting germline
mutations (PTEN, RASA, and TEK) was obtained for the retrospective
cohort. Data could therefore only be analyzed anonymously at the
group level. Based on very low variant allele frequencies in our TEK
positive cases (all 12% or lower [see Table]) none of the identified
variants were likely germline mutations. As a consequence, we
repeated the analyses for GNA11, GNAQ, KRAS, and TEK mutated
cases to correlate phenotype and genotype. To increase the size of
the anonymous group we also excluded the 27 PIK3CA-mutated
cases because clinical (and histopathological) characteristics are well-
studied.25,26
Genetic data from our entire prospective cohort were correlated
with clinical and histopathological features.
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3 | RESULTS
3.1 | Molecular results
The identified pathogenic and likely pathogenic variants are listed in
Table 1 and Supporting Information Table S2 (all PIK3CAmutated cases).
3.1.1 | The spectrum of gain of function (hotspot
mutations)
Prospective cohort
Nineteen out of 217 prospective cases obtained insufficient coverage.
Of the remaining 198 cases, 77 had mutations: 53 PIK3CA, 6 GNAQ,
6 KRAS, 3 IDH1, 3 GNA11, 1 NRAS, and 1 AKT1 pathogenic mutations.
Four cases harbored two mutations: PIK3CA and GNA11 (n = 2),
PIK3CA and GNAQ, and PIK3CA (n = 1) and IDH1 (n = 1).
Retrospective cohort
In the retrospective cohort (n = 102), 14 samples were excluded due
to insufficient coverage. Among the remaining 88 cases, 45 cases had
mutations: 27 PIK3CA, 11 TEK (one with two mutations in cis, TEK: c.
[2690A > G; c.2752A > G], p.([Tyr897Cys; Arg918Cys]), three KRAS,
one GNAQ and one GNA11 hotspot mutation. There was one case
with double-mutations in PIK3CA and GNAQ and one affecting
PIK3CA and IDH1. Mutations and histological types of both cohorts
are shown in Figure 1.
Overall, we discovered gain of function (hotspot) mutations in a
total of 122 cases (43%), with allele frequencies ranging from 2% to
24%. The mutant allele frequencies of 72% of cases (n = 88) were
below the presumed detection limit of 10% for Sanger and first gener-
ation NGS approaches (Figure 2). Six of all mutated cases (5%) har-
bored a combination of known pathogenic mutations in PIK3CA with
mutations in GNA11, GNAQ, or IDH1 with comparable mutant allele
frequencies (Figure 3).
3.1.2 | Loss of function mutations
In addition to the mutations investigated earlier, the retrospective
cohort (n = 88/102) was analyzed for loss of function mutations in
PTEN, RASA1, ACVRL1, ENG, and relevant exons of GLMN. We identi-
fied pathogenic loss of function mutations in PTEN (9 cases) and
RASA1 (1 case) (Figure 4), mutually exclusive with the earlier described
hotspot mutations. Six cases had mutant allele frequencies >40%.
Because the tissue selection for DNA isolation in these cases was
identical to the other cases in the cohort and mutant allele frequen-
cies >40% were not identified for any of the other genes, this was
interpreted as being germline variants in one RASA1 positive case and
at least 4 out of 9 PTEN positive cases. In 3 of these 6 cases with a
variant allele frequency >40% a potential second hit was observed at
a lower allele frequency (≤10%), indicative of a combination of a germ-
line pathogenic mutation with a mosaic second hit. In the fifth possi-
ble PTEN germline case, the variant allele frequency of 71% suggested
loss of the wild type allele and thus complete loss of a functional PTEN
copy in a subset of cells. We did not find any pathogenic inactivating
variants in GLMN, ENG, and ACVRL1, making the presence of muta-
tions less likely, although horizontal and vertical coverage may have
been insufficient to exclude low mosaic mutations (unique coverage
of both activating and inactivating genes is shown in Supporting
Information Tables S3 and S4). Also unique coverage of RASA1 was
insufficient to exclude the presence of mutations in other cases.
3.2 | Clinical data
The PIK3CA mutated lesions were mainly low flow (lymphatic and/or
venous) malformations, but comprised heterogeneous clinical aspects
as reported in the literature.2,25,26 Three patients had clinical charac-
teristics of Klippel Trenaunay syndrome (Table 1).
The clinical data of the 42 cases harboring hotspot mutations
other than PIK3CA are shown in Table 1. Briefly, 21 patients were
female and 21 were male aged between 2 and 81 years (median
35 years and mean 38 years). Patients had diverse clinical presenta-
tions with lesions arising at various anatomical sites with most of them
localized in the subcutis/skin (n = 30). Other lesions were located in
soft tissue (n = 6), bone (n = 3), (epi)dural (n = 2), and intracerebral
(n = 1). Two patients had a vascular malformation associated with
other anomalies in the context of Proteus (n = 1), and Sturge Weber
syndromes (n = 1). The case with a double mutation in TEK clinically
fitted well with a Blue Rubber Bleb Nevus (BRBN) syndrome.
Of the cases with double mutations, the first case with a PIK3CA
and GNAQ mutation was an intraosseous/dural vascular lesion and
the second case was a small relatively well-circumscribed high flow
skin lesion. One of the two cases with both a PIK3CA and a GNA11
mutation concerned a low flow lesion in the nose with bleeding. The
clinical information of the other case was unknown. Finally, the two
cases with both a PIK3CA and an IDH1 mutation were both clinically
atypical vascular skin lesions localized on the site of the scapula and
the leg, respectively. Overall, these 6 cases had no special clinical signs
indicating their double mutations.
Reasons for obtaining tissue were also diverse. In 13 patients a
diagnostic biopsy was taken for genetic analysis. In 17 cases tissue
was surgically removed for various reasons: for correction (n = 7), to
reduce pain (n = 3), and because of progression (n = 5) involving one
case with paraplegia due to an epidural mass and twice an amputation
of a lower leg and a finger, respectively. Other reasons were treat-
ment of varicosity, phlebitis, and a debulking resection because of a
massive lesion in the upper lip. Only sparse clinical information was
available for 12 patients.
3.3 | Correlation of histology and molecular findings
The PIK3CA mutated cases depicted variable histology ranging
from simple to combined capillary, lymphatic, and venous malfor-
mations and AVMs. All 11 cases with activating mutations in TEK
were noncircumscribed mostly combined venous, capillary, and/or
lymphatic lesions without an arterial component. Eight of the
eleven cases with RAS (9 KRAS, 1 NRAS, and 1 RASA1) mutations were
well-circumscribed capillary and/or venous/cavernous malformations
(Figure 5). The remaining 2 cases were noncircumscribed AVMs
(Figure 6). Two of three cases with an IDH1 mutation, were typical
spindle cell hemangiomas (SCH) and the third sample showed an intra-
muscular veno-capillary malformation. All 4 GNA11 mutated cases had
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TABLE 1 Clinical information and all (likely) pathogenic mutations and mutant allele frequencies identified in the prospective and retrospective
cohorts are listed (with the exception of the 80 PIK3CA mutations, see Supporting Information Table S1)
Gene Identified variant(s)
Variant
allele
frequency
(%)
Age/
sex Site Clinical features Histology
Prospective panel
GNA11 c.627G > C (p.Gln209His) 9 64/m Hand Unknown Veno-capillary
malformation
GNA11 c.547C > T (p.Arg183Cys) 5 61/m Upper eyelid Congenital port wine stain;
progressive hypertrophy
Veno-capillary
malformation
GNA11 c.626A > T (p.Gln209Leu) 3 72/m Acetabulum Unknown Veno-capillary
malformation
GNAQ c.548G > A (p.Arg183Gln) 8 67/f Skin neck Residue after venous
malformation
Veno-capillary
malformation
GNAQ c.627A > C (p.Gln209His) 4 57/f Arm Atypical lesion; spectrum
non-involuted congenital
hemangioma (NICH)/
venous malformation
Veno-capillary
malformation
GNAQ c.548G > A (p.Arg183Gln) 8 81/f Lower lip Port wine stain in Sturge
Weber Syndrome
Combined vascular
malformation
GNAQ c.627A > C (p.Gln209His) 18 64/f Epidural Epidural mass Veno-capillary
malformation
GNAQ c.548G > A (p.Arg183Gln) 8 43/f Upper lip Port wine stain with firm
hypertrophy; KTS
spectrum
Venous malformation
GNAQ c.626A > T (p.Gln209Leu) 21 15/m Skin clavicle Non congenital vascular high
flow lesion
Veno-capillary
malformation
AKT-1 c.49G > A (p.Glu17Lys) 8 5/m Saphenous vein Congenital port wine stain of
one leg with firm
overgrowth; mild
phenotype of Proteus.
Venous malformation
KRAS c.35_38delinsCTCA
(p.Gly12_Gly13delinsAlaHis)
32 56/f Flank Vascularized tumor Veno-capillary
malformation
KRAS c.64C > A (p.Gln22Lys) 22 32/m Cheek KTS-spectrum with
lymphedema and port-
wine stain leg and multiple
vascular lesions left side
face
Veno-capillary
malformation
KRAS c.35G > C (p.Gly12Ala) 18 32/m Cheek Lipoma with vascular lesion Venous malformation
KRAS c.436G > A (p.Ala146Thr) 17 45/f Arm KTS spectrum with
venolymphatic lesion and
port wine stain
Venous malformation
KRAS c.37G > T (p.Gly13Cys) 2 8/f Lower jaw Unknown Veno-capillary
malformation
KRAS c.35G > A (p.Gly12Asp) 9 70/f Subcutis buttock Unknown Veno-capillary
malformation
NRAS c.182A > G (p.Gln61Arg) 14 12/m Thoracal skin Multiple eruptive pyogenic
granuloma
Capillary malformation
IDH1 c.394C > T (p.Arg132Cys) 2 12/f Upper arm muscle Venous malformation or
non-involuted congenital
hemangioma
Veno-capillary
malformation
IDH1 c.394C > T (p.Arg132Cys) 14 38/f Foot Unknown SCH
IDH1 c.394C > T (p.Arg132Cys) 10 15/m Soft tissue foot Unknown SCH
PIK3CA; GNAQ c.3140A > G (p.His1047Arg);
c.627A > C (p.Gln209His)
26; 26 53/m Skull/dura Vascular proliferation with
Masson-like features
Veno-capillary
malformation
PIK3CA; GNA11 c.3140A > G (p.His1047Arg);
c.627G > C (p.Gln209His)
17; 17 57/m Skin pericumbilical Unknown Veno-capillary
malformation
PIK3CA; GNA11 c.1633G > A (p.Glu545Lys);
c.627G > T (p.Gln209His)
7; 6 45/m Skin nose Venous malformation Veno-capillary
malformation
PIK3CA; IDH1 c.3140A > G (p.His1047Arg);
c.394C > T (p.Arg132Cys)
12; 9 5/f Scapula Venolymphatic
malformation, atypical by
ultrasound
SCH
(Continues)
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a veno-capillary morphology. Of the 7 cases with a GNAQ mutation,
4 were veno-capillary malformations, 2 VMs, and 1 had combined fea-
tures including an arterial component. The AKT1 mutated case con-
sisted of veins only. The 2 cases harboring an IDH1 and PIK3CA
mutation were SCHs. The other 4 cases with a PIK3CA mutation com-
bined with either a GNA11 (n = 2) or GNAQ (n = 2) mutation were all
veno-capillary malformations. Histology of the RASA1 and PTEN
mutated cases could not be determined due to anonymization.
In the prospective cohort (n = 198/217), mutations and the per-
centages of mutated cells within the histologically determined groups
are shown in Supporting Information Table S5.
The spectrum of mutations per group was, based on clinical and
histological features, relatively heterogeneous. The capillary malfor-
mations, for example, showed 3 GNAQ and 3 KRAS mutations, 1 NRAS
and 1 PIK3CA mutation, and also a combined PIK3CA with GNA11
mutation. In AVMs (4 out of 17) and LMs (8 out of 14), without excep-
tion however, PIK3CA mutations were identified.
4 | DISCUSSION
Vascular malformations belonging to the spectrum of overgrowth syn-
dromes are, in most cases, genetically characterized by somatic mosaic
pathogenic hotspot mutations or, more rarely, by germline mutations.1
We analyzed frequently mutated positions in more than 20 genes in
clinically/radiologically and/or histopathologically diagnosed vascular
malformations/overgrowth syndromes to gain more insight into their
molecular biology linked to clinicopathological characteristics.
4.1 | Technical challenges for molecular diagnostics
The range of identified mutant allele frequencies shows that it is highly
valuable to analyze vascular malformations with NGS, especially with the
inclusion of UMIs allowing an analytical sensitivity of 1% variant allele fre-
quency in sequence analyses of FFPE tissue. At least 65% of mutations
would have been missed using Sanger sequencing, based on a detection
TABLE 1 (Continued)
Gene Identified variant(s)
Variant
allele
frequency
(%)
Age/
sex Site Clinical features Histology
Retrospective panel
TEK c.2690A > G (p.Tyr897Cys) 3 11/f Jaw Venous malformation Venous malformation
TEK c.2740C > T (p.Leu914Phe) 5 20/f Labia minora Venous malformation Venous malformation
TEK c.2740C > T (p.Leu914Phe) 11 15/m Soft tissue leg Venous malformation Veno-capillary
malformation
TEK c.2740C > T (p.Leu914Phe) 9 67/f Upper lip Venous lake Combined malformation
(extensive lymphatic
component)
TEK c.2690A > G (p.Tyr897Cys) 4 80/f Subcutis Unknown Combined malformation
(extensive lymphatic
component)
TEK c.2690A > G (p.Tyr897Cys) 4 9/f Groin Venous malformation, also
anemia. d.d. Blue rubber
bleb nevus.
Combined malformation
(extensive lymphatic
component)
TEK c.2740C > T (p.Leu914Phe) 8 33/m Lower arm Venous malformation Venous malformation
TEK c.2740C > T (p.Leu914Phe) 5 17/f Leg Unknown Veno-capillary
malformation
TEK c.2740C > T (p.Leu914Phe) 5 10/m Lip Venous malformation Veno-capillary
malformation
TEK c.2740C > T (p.Leu914Phe) 9 15/m Soft tissue arm Unknown Veno-capillary
malformation
TEK c.2689 T > C (p.Tyr897His) 12 2/m Arm Localized atypical tumor by
ultra sound. d.d. vascular
malformation
Veno-capillary
malformation
GNAQ c.548G > A (p.Arg183Gln) 7 56/f Face Port wine stain with
hypertrophy
Venous malformation
KRAS c.34G > T (p.Gly12Cys) 6 76/m Lower leg Arteriovenous malformation
(AVM) with ulceration
AVM
KRAS c.34G > T (p.Gly12Cys) 6 68/f Finger AVM AVM
KRAS c.35G > T (p.Gly12Val) 3 17/f Brain Unknown Venous malformation
GNA11 c.626A > T (p.Gln209Leu) 9 45/m Skin ear canal Unknown Veno-capillary
malformation
PIK3CA; GNAQ c.1624G > A (p.Gln542Lys);
c.627A > C (p.Gln209His)
15; 13 27/m Skin High flow lesion, d.d. AVM Veno-capillary
malformation
PIK3CA; IDH1 c.1624G > A (p.Gln542Lys);
c.394C > T (p.Arg132Cys)
24; 20 21/m Subcutis leg Atypical vascular lesion SCH
Abbreviations: KTS, Klippel Trenaunay syndrome; AVM, arteriovenous malformation; SCH, spindel cell hemangioma.
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level of at least 10%mutant alleles. More sensitive techniques such as digi-
tal droplet PCR would potentially result in identification of more patho-
genic mutations.27 However, the variety of mutations in combination with
limited amounts of affected cells and available tissue require an approach in
which a larger number of positions can be tested simultaneously. The iden-
tified low frequency pathogenic variants are in linewith themosaicism.
The detection of mosaic mutations with variant allele frequencies
<10% in gDNA from FFPE tissue depends on quality and quantity of
isolated gDNA and the presence of cytosine deamination resulting in
C:G > T:A mutations. False-negative calls can result from the overesti-
mation of the actual number of analyzed DNA molecules and potential
false-positive calls can arise from deamination artifacts.
4.2 | Vascular malformations span a mutational
spectrum affecting multiple signaling pathways
4.2.1 | PI3K/AKT/mTOR pathway
Activating mutations in PIK3CA, AKT1, and TEK, and alternatively dis-
rupting mutations in PTEN, activate the mTOR pathway, regulating cell
growth, proliferation, survival and cell cycle progression.2,6,28,29
PIK3CA mutations are the most ubiquitous ones in vascular malforma-
tions. This was reflected in our cohorts with ~30% (n = 86) of the
cases being affected. They show a variable phenotype both histologi-
cally (LMs, VMs, and AVMs) and clinically (low flow malformations),
which is in accordance with the literature.26,30 AKT1 was mutated in
only 1 case (~0.3%) of the retrospective cohort, showing a p.Glu17Lys
mutation, the same mutation that has been most frequently described
in the literature.12 Mutations in TEK/TIE2 with about 85% of cases
harboring a p.[Leu914Phe] missense mutation results nearly exclu-
sively in venous malformations.31–33 In our retrospective cohort,
11 cases (12.5%) were mutated. A c.2740C > T (p.(Leu914Phe)) muta-
tion was found in 7 of them. Other mutations we identified were
c.2690A > G (p.[Tyr897Cys]) (n = 3) and c.2689 T > C (p.[Tyr897His])
(n = 1) indicating that only screening of p.(Leu914Phe) is insufficient.
Clinically, all cases had a venous phenotype including 1 case with a
BRBN syndrome. Both TEK mutations found in the BRBN case were
present in cis. As all mutated reads contained both mutations, the
same variant allele frequency was suggested.34 In contrast to the
FIGURE 1 Overview of prospective and retrospective vascular malformation cohort. NGS-based sequence analyses of a total of 319 cases of
vascular malformations was performed in a routine diagnostic (prospective) and retrospective cohort consisting of histologically confirmed
vascular anomalies. Molecular results grouped per mutated gene (top) and the clinicopathological entities in both cohorts (bottom). Abbreviations:
AVM, arteriovenous malformation; SOGS, somatic overgrowth syndrome
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literature,31–33 our TEK mutated cases were histologically more het-
erogeneous showing also combined lesions with a venous, capillary,
and/or a lympathic component.
The retrospective cohort contained 9 PTEN mutated cases (~10%)
(see later), adding up to a total of 107 cases containing mutations
indicative of mTOR activation in the PI3K/AKT/mTOR pathway.
4.2.2 | RAS–RAF–MEK–ERK signaling pathway
RAS signaling can be stimulated by both activating (somatic) mutations
in KRAS, HRAS, NRAS as well as inactivating (germline) mutations in
RASA1, which is a RAS-GAP (Guanine Activating Protein) and negative
regulator of the RAS–RAF–MEK–ERK signaling pathway. Subse-
quently, diverse cellular signaling networks including the mTOR and
ERK pathways are activated.35 Histologically, in contrast with the het-
erogeneity seen for the other mutations, 8 out of 11 RAS mutated
vascular malformations were well-circumscribed (capillary and/or
venous), while lesions with other mutations were almost all
noncircumscribed.
GNAQ is a gene encoding guanine nucleotide binding protein G(q)
alpha, a subunit within a complex that hydrolyses the intracellular
messenger GTP to GDP.36 GNA11 and GNA14 are analogous binding
proteins with nearly the same protein sequence as GNAQ.18,36 When
mutated, these genes induce changes in cellular morphology and cell
growth by upregulation of mainly the RAS-RAF-MEK-ERK pathway.18
Combining the two cohorts, we detected 9 KRAS, 1 NRAS,
7 GNAQ, and 4 GNA11 hotspot mutations; GNAQ and GNA11 were in
2 cases each combined with a PIK3CA mutation. These, and one inac-
tivating mutation in RASA1, suggest a more significant role (about 8%
of all the included cases) of the RAS-RAF-MEK-ERK pathway in vas-
cular malformations than may be expected from the literature.15,16
We did not detect GNA14 mutations. This is in accordance with
the literature reporting that such mutations are restricted to tufted
hemangioma and kaposiform hemangioendothelioma, which were not
included in our cohorts.22
4.3 | IDH 1/2 mutated vascular lesions are
malformations rather than tumors
Five cases showed an IDH1mutation, in two cases in combination with
a PIK3CA mutation (one of these cases was included in a previously
published cohort37). Isocitrate dehydrogenases (IDH) are metabolic
enzymes which, as a result of a somatic mutation (in both IDH1 and
IDH2), mostly inhibit the catalyzation of isocitrate to α-ketoglutarate
FIGURE 2 Mutant allele frequencies of identified mutations. The
mutant allele frequencies of all (likely) pathogenic mutations in both,
the prospective (top) and retrospective (bottom) cohort, grouped
per gene
FIGURE 3 Mutant allele frequencies in cases with two pathogenic
hotspot mutations. In 6 cases, a combination of one PIK3CA with an
additional pathogenic activating (GNA11 and GNAQ) or transforming
(IDH1) hotspot mutation was identified. The mutant allele frequencies
of both mutations are depicted and connected per case
FIGURE 4 Mutant allele frequencies in cases with disrupting
mutations. In 10 cases of the retrospective cohort, disrupting
mutations were identified in PTEN (9 cases) and RASA1 (1 case). In a
subset of cases, an additional mutation was found. The mutant allele
frequencies are depicted per case, with connected data points in case
two mutations were identified
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(α-KG). This results in aberrant DNA methylation and histone modifica-
tion leading to stabilization of hypoxia inducible factor-1α subse-
quently inducing angiogenesis.38 Four of our cases were spindle cell
hemangiomas (SCH), in line with previous findings.37 Interestingly, the
fifth lesion was a small biopsy of an intramuscular veno-capillary mal-
formation without a spindle cell component. Vice versa, we also found
a SCH with only a PIK3CAmutation (17% variant allele frequency) con-
firming that SCHs belong to the heterogeneous spectrum of vascular
malformations rather than to vascular tumors.4,37
4.4 | Combined mutations
In 6 cases we identified a combination of an activating mutation in
PIK3CA with an additional pathogenic mutation in GNAQ, GNA11, or
IDH1. As these cases had a heterogeneous/combined phenotype
without specific clinical symptoms, no conclusion can be drawn
regarding the significance of the dominant mutation.
To our knowledge, such a combination of mutations in two
individual genes in vascular malformations/overgrowth syndromes
has not been reported before. It is likely that this can be explained
by the presence of two related events in the same cells, because in
all cases the mutant allele frequencies of both mutations were very
similar. However, an in situ approach would be required to formally
prove this concept. From a signaling perspective, the pathogenic
mutations in GNAQ, GNA11, and IDH1 are expected to provide
additional growth advantage in parallel with PIK3CA-driven mTOR
activation. One could argue that different pathways in parallel are
involved in aberrant development of vascular structures and other
FIGURE 5 Venous/cavernous malformation. HE, ×100 [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 6 Arteriovenous malformation showing variation in wall thickness. HE, ×20 [Color figure can be viewed at wileyonlinelibrary.com]
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affected tissue. This may be relevant information if application of
targeted treatments is considered.
4.5 | Potential germline aberrations in cases of
vascular anomalies
Pathogenic germline mutations in PTEN lead to PTEN hamartoma
tumor syndrome (PHTS) with susceptibility to multiple tumors as well
as vascular malformations. This process is initiated after loss or inacti-
vation of the second (wild type) allele by somatic mutation resulting in
increased levels of PIP3 and increased activation of AKT.29 We found
9 cases (approximately 10% of the cases) with a (likely) pathogenic
PTEN mutation, of which at least 4 were a germline mutation, in the
retrospective cohort. This unexpectedly high percentage of PTEN
mutations suggests a much more important role in the etiology of spo-
radic vascular malformations than anticipated, as PTEN-associated
anomalies are only described in the context of PHTS.29,39
We also identified 1 case with a potential germline RASA1 muta-
tion. Because data from our retrospective cohort were analyzed anon-
ymously, we could not associate the PTEN and RASA1 positive lesions
to individual histological and clinical characteristics. However, a vascu-
lar malformation may well represent the first clinical presentation of
an eventually more extensive syndromal phenotype, which is espe-
cially relevant in the context of de novo germline mutations or atypi-
cal phenotypic presentation. Our findings urge for clinical awareness
of this potentially unrecognized patient group of vascular malforma-
tions at risk for germline-associated tumors.
Complete analyses of all coding and splice site sequences is
required to identify all disrupting mutations, in contrast to the afore-
mentioned “hotspot” analyses; this is challenging when using relatively
poor quality gDNA obtained from FFPE tissue. Due to limitations in
horizontal and vertical coverage for ACVRL1, ENG, and GLMN, but also
PTEN and RASA1, pathogenic disruptions in these genes may have
been remained undetected.
4.6 | Therapeutic opportunities for vascular
malformations
There is increasing evidence28,40 that sirolimus, an mTOR inhibitor,
can be used to treat a subset of the vascular malformations with a
more favorable balance between effect and side effects than conven-
tional treatments like surgery, embolization, or laser therapy.41 The
precise mechanism behind this treatment is still unknown, but at least
107 of 286 cases in our series harbored mutations predicted to acti-
vate mTOR signaling. These mTOR activating cases are not limited to
PIK3CA, so a more comprehensive analysis including additional genes
involved in this pathway could increase the diagnostic and therapeutic
yield (in our set-up by ~25%). Similarly, MEK inhibitors seem to be a
promising therapeutic agent for lesions harboring mutations involved
in the RAS-RAF-MEK-ERK pathway16; such mutations were found in
25 of our cases. The mapping of causative and druggable mutations
by sequencing appears to be a big promise for patients with hitherto
hardly treatable conditions in the vascular anomalies spectrum. Clini-
cal trials with sirolimus with favorable initial results exemplify the
potency of this new medical approach.42,43
5 | CONCLUSION
In summary, mutational analysis of vascular malformations is of high
diagnostic value and an indispensable addition to regular diagnostics,
because clinical, radiological, and pathological investigations often
offer insufficient clarity. Furthermore, it can provide clues for an
underlying hereditary condition due to a germline mutation. In addi-
tion, increased knowledge of pathogenic mutations present in these
lesions can stratify patients for targeted therapeutic options.15,40,44 A
comprehensive and sensitive analysis is required because of the spec-
trum of genes involved and the mosaicism with low levels of mutated
cells and also combined mutations.
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